Targeting high-mobility-group-box-1-mediated inflammation: a promising therapeutic approach for myocardial infarction

Area of Science:

• Cardiology
• Molecular Biology
• Immunology

Background:

• Myocardial infarction (MI) involves inflammation and cell death, worsening ischemia and reperfusion injury.
• High mobility group box-1 (HMGB1), a nucleoprotein, acts as both a chromosomal stabilizer and an inflammatory mediator.
• Extracellular HMGB1 released during ischemia functions as a damage-associated molecular pattern, initiating immune responses and inflammation.

Purpose of the Study:

• To review the multifaceted role of HMGB1 in the pathogenesis of myocardial infarction.
• To summarize recent findings on HMGB1's function in ischemic conditions.
• To explore HMGB1's potential as a therapeutic target for MI.

Main Methods:

• Literature review of studies investigating HMGB1 in myocardial ischemia.
• Analysis of HMGB1's involvement in key signaling pathways (PI3K/Akt, TLR4/NF-κB, RAGE/HMGB1).
• Examination of HMGB1's impact on angiogenesis, apoptosis, and inflammation in the context of MI.

Main Results:

• HMGB1 signaling pathways are implicated in promoting angiogenesis, apoptosis, and modulating inflammation.
• HMGB1 acts as a critical mediator in the inflammatory cascade during myocardial ischemia and reperfusion.
• HMGB1's dual role in chromosomal stability and inflammatory response is highlighted.

Conclusions:

• HMGB1 significantly contributes to the pathogenesis of myocardial infarction.
• Targeting HMGB1 mechanisms may offer novel therapeutic strategies to mitigate MI severity.
• Further understanding of HMGB1's role is crucial for improving patient outcomes in MI.